AR and benign prostatic hyperplasia: Several OS-targeting drugs demonstrate therapeutic efficacy in BPH: Berberine (BBR; reduces serum testosterone/DHT and inhibits OS) (106); palmitoylethanolamide (um-PEA) and baicalein (Baic; modulate AR signaling and attenuate OS) (107).